Moderna Inc. has agreed to pay $950 million to settle all global litigation with Arbutus Biopharma Corp. and Genevant Sciences GmbH concerning its current and future vaccines, with no additional royalties. Moderna plans to assert government-contractor immunity to potentially limit further liability. If this claim is not upheld, the company may owe an additional payment of up to $1.3 billion.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Moderna to Pay Almost $1 Billion to Settle Arbutus Litigation
Moderna Inc. has agreed to pay $950 million to settle all global litigation with Arbutus Biopharma Corp. and Genevant Sciences GmbH concerning its current and future vaccines, with no additional royalties. Moderna plans to assert government-contractor immunity to potentially limit further liability. If this claim is not upheld, the company may owe an additional payment of up to $1.3 billion.